GeneDx Holdings Corp. (WGS)
| Market Cap | 3.47B |
| Revenue (ttm) | 362.32M |
| Net Income (ttm) | 1.41M |
| Shares Out | 28.73M |
| EPS (ttm) | 0.05 |
| PE Ratio | 2,470.95 |
| Forward PE | 56.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 327,707 |
| Open | 117.05 |
| Previous Close | 118.42 |
| Day's Range | 114.40 - 121.58 |
| 52-Week Range | 54.14 - 136.00 |
| Beta | 2.04 |
| Analysts | Strong Buy |
| Price Target | 102.14 (-15.54%) |
| Earnings Date | Oct 28, 2025 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut. [Read more]
Financial Performance
In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $102.14, which is a decrease of -15.54% from the latest price.
News
GeneDX CEO Katherine Stueland on how the company is using AI to save lives
GeneDX CEO Katherine Stueland discusses how the company is using AI to help deliver "life-changing information." Want to hear the full interview?
GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company
GeneDX CEO Katherine Stueland talks about the impact of federal funding cuts to research programs. Want to hear the full interview?
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map vari...
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gros...
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseas...
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer.
GeneDx to Partner with Florida's Sunshine Genetics Network, Launching Nation's First State-Backed Genomic Newborn Screening Program
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced its involvement in the Sunshine Genetics Act, establishing the nation's first state-backed genomic newborn screening program.
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the Autism Partnership Program to expand access to exome and genome testing in partnership with Jaguar Gene Therapy.
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting.
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025.
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the launch of BEACONS, the nation's first multi-state genomic newborn screening initiative.
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the appointment of Lisa Gurry as Chief Business Officer, effective immediately.
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx's Infinity...
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors.
GeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Katherine Stueland - President, CEO & Director Kevin Feel...
Seer Appoints Isaac Ro to its Board of Directors
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to ...
Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS)
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder litigation firm, alerts investors that it is investigating whether GeneDx Holdings Corp. (“G...
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.
GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement ra...
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group
LOS ANGELES , July 31, 2025 /PRNewswire/ -- News provided by DJS Law Group LLP The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NA...
GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options
Katherine Stueland, GeneDx CEO, joins 'Squawk Box' to discuss diagnosing children with rare diseases, cost structure of the tests, the fight against rare diseases, company growth outlook, deployment o...
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Offi...
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2025.
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp...